Enzo Biochem introduces new lung cancer diagnostic test in US

14 November 2012 (Last Updated November 14th, 2012 18:30)

Enzo Biochem's Clinical Labs has announced the availability of a new diagnostic test, designed to assess and detect lung cancer at earlier stages, in New York metropolitan market as well as New Jersey and Eastern Pennsylvania, US.

Enzo Biochem's Clinical Labs has announced the availability of a new diagnostic test, designed to assess and detect lung cancer at earlier stages, in New York metropolitan market as well as New Jersey and Eastern Pennsylvania, US.

The EarlyCDT-Lung test uses a panel of tumor antigens to detect the presence of cancerous cells in patients who are at high risk of developing lung cancer including heavy smokers, those exposed to suspect environmental conditions and patients with a CT nodule under surveillance.

Developed in collaboration with Kansas-based Oncimmune, the immuno-biomarker platform (EarlyCDT-Lung) provides increased sensitivity, while maintaining higher levels of specificity than other single or multiple antigen tests, according to the company.

"The EarlyCDT-Lung test uses a panel of tumor antigens to detect the presence of cancerous cells in patients who are at high risk of developing lung cancer including heavy smokers, those exposed to suspect environmental conditions and patients with a CT nodule under surveillance."

Oncimmune CEO Dan Calvo said the company is pleased to partner with Enzo Clinical Labs in offering its EarlyCDT-Lung assay in the metropolitan New York area.

"Enzo Labs' outstanding facilities and experienced personnel make Enzo an ideal partner to make available this important assay, which we believe can improve the wellbeing of the many individuals at risk for developing lung cancer," Calvo said.

Enzo Biochem president Barry Weiner said the company is focused on providing molecular and esoteric diagnostics that medical practitioners increasingly are relying upon to more timely and effectively predict and treat diseases.

"The EarlyCDT-Lung agreement is recognition of our Clinical Lab's ability to reach an important segment of physicians in one of the nation's major market area and of our capability for delivering outstanding assay results, which we have demonstrated with our ColonSentry offering," Weiner said.

"ColonSentry, since its introduction just a few months ago, is growing in use as an early warning test for indications of possible colorectal cancer and the need for a colonoscopy for more extensive investigation.

"Similarly, EarlyCDT-Lung, when used in conjunction with diagnostic imaging, has the potential to aid in the identification of possible lung cancer when treatment can be most successful at a very early stage."